Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog

Blood

Volumn 102, Issue 10, 2003, Pages 3743-3752

  Zhang, Yuxiang ^b   Dawson, Marcia I ^b   Ning, Yangmin ^b   Polin, Lisa ^b   Parchment, Ralph E ^b   Corbett, Thomas ^b   Mohamed, Anwar N ^b   Feng, Kai Chia ^b   Farhana, Lulu ^b   Rishi, Arun K ^b   Hogge, Donna ^b   Leid, Mark ^b   Peterson, Valerie J ^b   Zhang, Xiao Kun ^b   Mohammad, Ramzi ^b   Lu, Jing Song ^b   Willman, Cheryl ^b   VanBuren, Eric ^b   Biggar, Sandra ^b   Edelstein, Mark ^b   Eilender, David ^b   Fontana, Joseph A ^a   more..

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 3 CHLOROCINNAMIC ACID; CASPASE; CELL NUCLEUS RECEPTOR; CINNAMIC ACID DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL XL; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLAST CELL; CANCER RESISTANCE; CELL PROLIFERATION; COLONY FORMATION; COLONY FORMING UNIT M; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME DEGRADATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; RECEPTOR UPREGULATION;

EID: 0242494811     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-01-0108     Document Type: Article

References (79)

1. Berman E. Recent advances in the treatment of acute leukemia. Curr Opin Hematol. 2000;4:205-211.
2. Bruservd O, Gjertsen BT. New strategies for the treatment of acute myelogenous leukemia: differentiation induction-present use and future possibilities. Stem Cells. 2000;18:157-165.
3. Saez RA, Therapeutic options in the management of acute myelogenous leukemia in adults. Cancer Control. 1997;4:399-406.
4. Bruservd O, Tjonnfijord G, Gjertjen BT, Foss B, Ernst P. New strategies in the treatment of acute myelogenous leukemia: mobilization and transplantation of autologous peripheral stem cells in adult patients. Stem Cells. 2000;18:343-351.
5. Stein AS, O'Connell MR, Slovak ML, et al. High dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia. 2000;14:1191-1196.
6. Chen ZX, Xue YQ, Zhang R, et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood. 1991;78:1413-1419.
7. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia, I: clinical results. Blood. 1990;76:1704-1709.
8. Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324:1385-1393.
9. Mangelsdorf DJ, Umesono K, Evans RM. The retinoid receptors. In: Sporn MB, Roberts AB, Goodman DS, eds. The Retinoids Biology, Chemistry and Medicine. New York, NY: Raven Press; 1994:319-350.
10. Rousselot P, Hardas B, Patel A, et al. The PML-RARα gene product of the t(15:17) translocation inhibits retinoic acid-induced granulocyte differentiation and mediated transactivation in human myeloid cells. Oncogene. 1994;9:545-551.
11. Early E, Moore MAS, Kakizuka A, et al. Transgenic expression of PML/RARα impairs myelopoiesis. Proc Natl Acad Sci U S A. 1996;93:7900-7904.
12. Doucas V, Brocues JP, Yaniv M, de The H, Dejean A. The PML retinoic acid receptor α translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1. Proc Natl Acad Sci U S A. 1993;90:9345-9349.
13. Weiss K, Rambaud S, Lavan K. Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell. 1994;76:345-354.
14. Melnick A, Licht JD. Deconstructing a disease: RARα its fusion partners and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-3215.
15. Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic cells in primary culture in response to retinoic acid. Blood. 1981;57:1000-1004.
16. Bennett JB, Catovsky D, Daniel MT, et al. Proposed criteria for the classification of acute myeloid leukemia: a report of the French-American-British Group. Ann Intern Med. 1985;103:620-625.
17. Shao ZM, Dawson MI, Li XS, et al. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in breast cancer cells. Oncogene. 1995;11:493-504.
18. Schadendorf D, Kern MA, Phal HL, et al. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol. 1996;135:1889-1898.
19. Oridate N, Higuchi M, Suzuki S, Shroot B, Hong WK, Lotan R. Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6-[3-(1-adamantyl)hydroxyphenyl]-2-naphtalenecarboxylic acid (CD437). Int J Cancer. 1997;70:484-487.
20. Sun SY, Yue P, Shroot B, Hong WK, Lotan R. Induction of apoptosis in human non-small cell lung carcinoma cells by the synthetic retinoid CD437. J Cell Physiol. 1997;173:279-284.
21. Adachi H, Preston G, Harvat B, Dawson MI, Jetten AM. Inhibition of cell proliferation and induction of apoptosis by the retinoid AHPN in human lung carcinoma cells. Am J Respir Cell Mol Biol. 1998;18:323-333.
22. Bernard BA, Bernardon JM, Delesclose C, et al. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptorγ. Biochem Biophys Res Commun. 1992;186:977-983.
23. Chao WR, Hobbs PD, Jong L, et al. Effects of receptor class- and subtype-selective retinoids and an apoptosis-inducing retinoid on the adherent growth of the NIH:OVCAR-3 ovarian cell line in culture. Cancer Lett. 1997;115:1-7.
24. Lu XP, Fanjul A, Picard N, Shroot B, Pfahl M. A selective retinoid with high activity against androgen-resistant prostate cancer cell type. Int J Cancer. 1999;80:272-278.
25. Holmes WF, Dawson MI, Soprano D, Soprano KJ. Induction of apoptosis in ovarian cells by AHPN/CD437 is mediated by retinoid receptors. J Cell Physiol. 2000;185:61-67.
26. Hsu CA, Rishi AK, Li XS, et al. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor independent pathway. Blood. 1997;89:4470-4479.
27. Zhang Y, Dawson MI, Mohammad R, et al. Induction of apoptosis of human B-CLL and ALL cell by a novel retinoid and its non-retinoidal analog. Blood. 2002;100:2917-2925.
28. Thacker DJ, Hogge DE. Cytokine-dependent engraftment of human myeloid leukemia cell lines in immunosuppressed nude mice. Leukemia. 1994;8:871-877.
29. Koeffler HP, Golde DW. Acute myelogenous leukemia: a human cell line responsive to colony stimulating factor. Science. 1978;200:1153-1154.
30. Robertson KA, Emami B, Collins SJ. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood. 1992;1885-1889.
31. Nagy L, Thomazy VA, Shipley GL, et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol. 1995;15:3540-3551.
32. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV, Fontana JA. Mechanism of regulation of WAF1/CIP1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene. 1994;9:3407-3415.
33. Gavreli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
34. Whitacre CM, Hashimato T, Tsai ML, Chatterjee S, Berger SL, Berger NA. Involvement of NAD poly(ADP-ribose) metabolism in p53 regulation and its consequences. Cancer Res. 1995;55:3697-3701.
35. Sharpless T, Traganos F, Darzynkiewicz T, Melamed MR. Flow cytofluorimetry: discrimination between single cells and cell aggregates by direct size measurements. Acta Cytologica. 1975;19:577-581.
36. Parchment RE, Volpe DA, LoRusso PM, Erickson-Miller CL, Murphy MJ. In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacidine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine and canine marrow. J Natl Cancer Inst. 1994;86:273-280.
37. Corbett TH, Panchapor C, Polin L, et al. Preclinical efficacy of thioxanthone SR-271425 against transplanted solid tumors of mouse and human origin. Invest New Drugs. 1999;17:17-27.
38. Teicher BA. In vivo tumor response end points. In: Tumor Models in Cancer Research. Teicher B, ed. Totowa, NJ: Humana Press;2001:593-616.
39. Corbett T, Valeriote F, LoRusso P, et al. Tumor models and the discovery and secondary evaluation of solid tumor active agents. Int J Pharmacognosy. 1995(suppl);33:102-122.
40. Woo M, Hakem R, Soengas MS, et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev. 1998;12:806-819.
41. Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by caspase family proteases. J Biol Chem. 1999;274:20049-20052.
42. Widmann C, Gibson S, Johnson CL. Caspase-dependent cleavage of signaling proteins during apoptosis: a turn-off mechanism for anti-apoptotic signals. J Biol Chem. 1998;273:7141-7147.
43. Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci U S A. 1998;93:2239-2244.
44. Lazebnik YA, Kaufman SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a protease with properties like ICE. Nature. 1994;371:346-347.
45. Aravind L, Dixit VM, Koonin EV. Apoptotic molecular machinery: vastly increased complexity in vertebrates revealed by genome comparisons. Science. 2001;291:1279-1284.
46. Gross A, McDonnel JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899-1911.
47. Thomas A, El Rouby S, Reed JC, Krajewski S, Potmesil M, Newcomb, EW. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/ bax proteins in drug resistance. Oncogene. 1996;12:1055-1062.
48. Hanada M, Delia D, Aiello A, Stadmauer E, Reed JC. Bcl-2 gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82:1820-1828.
49. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood. 1997;89:630-643.
50. Boise LH, Garcia-Gonzalez M, Postema CE, et al. Bcl-X, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993;74:597-608.
51. Fujita N, Nagahashi A, Nagashima K, Rokudai S, Tsuruo T. Acceleration of apoptotic death after cleavage of bcl-XL protein by caspase-3 like protease. Oncogene. 1998;17:1293-1307.
52. Franklin RA, McCubrey JA. Kinases: positive and negative regulators of apoptosis. Leukemia. 2000;14:2019-2034.
53. Jarpe MB, Widmann C, Knall C. Anti-apoptotic versus pro-apoptotic signal transduction checkpoints and stop signs along the road to death. Oncogene. 1998;17:1475-1482.
54. Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatinum-induced apoptosis. J Biol Chem. 2000;275:39435-39443.
55. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000;288:870-874.
56. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239-252.
57. Zhang Y, Hang Y, Dawson M, et al. Activation of the p38 and JNK/SAPK mitogen activated protein kinase pathways during apoptosis mediated by a novel retinoid. Exp Cell Res. 1999;247:233-240.
58. Bradner WT, Pindell MH. Myeloid leukemia C1498 as a screen for cancer chemotherapeutic agents. Cancer Res. 1966;26:375-390.
59. Parchment RE, Gordon M, Grieshaber CK, Volpe D, Ghielmini M. Predicting hematological toxicity (myelosuppression) of cytoxic drug therapy from in vitro tests. Ann Oncol. 1998;9:357-364.
60. Cryns Y, Yuan J. Proteases to die for. Genes Dev. 1998;12:1551-1570.
61. Adachi H, Adams A, Hughes FM, Zhang J, Cidlowski JA, Jetten AM. Induction of apoptosis by the novel retinoid AHPN in human T-cell lymphoma involves caspase-dependent and independent pathways. Cell Death Differ. 1998;5:973-983.
62. Sun SY, Yue P, Wu GS, et al. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res. 1999;59:2829-2833.
63. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res. 2000;60:7149-7155.
64. Zou H, Henzel W, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4 participates in cytochrome c-dependent activation of caspase-3. Cell. 1997;90:405-413.
65. Tewari M, Quan LT, O'Rourke KO, et al. Yama/CPP32β, a mammalian homolog of CED-3, is a CRM A-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 1995;81:801-809.
66. Huang DCS, Adams JM, Cory S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J. 1998;17:1029-1039.
67. Clem RJ, Cheng EYH, Karp CL. Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci U S A. 1998;95:554-559.
68. Juo P, Kuo, CJ, Reynolds SE, et al. Fas activation of the p38 mitogen-activated protein kinase signaling pathway requires ICE/CED-3 family proteases. Mol Cell. Biol. 1997;17:24-35.
69. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK and p38 MAP kinases on apoptosis. Science. 1995;270:1326-1331.
70. Assefa Z, Vanteghem A, Garmyn M, et al. p38 mitogen-activated protein kinase regulates a novel caspase-independent pathway for the mitochondrial cytochrome C release in ultraviolet B radiation-induced apoptosis. J Biol Chem. 2000;275:21416-21421.
71. Yu R, Mandelkar S, Tan, TH, Kong ANT, Activation of p38 and c-jun N terminal kinase pathways and inhibition of apoptosis by chelerythrine do not require inhibition of protein kinase C. J Biol Chem. 2000;275:9612-9619.
72. Anderson P. Kinase cascades regulating entry into apoptosis. Microbiol Mol Biol. 1997;61:33-46.
73. Rice PL, Goldberg RJ, Ray EC, Driggers LJ, Ahnen DJ. Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res. 2001;61:1541-1547.
74. Xue L, Murray JH, Tolkovsky AM. The Ras/phosphatidylinositol 3-kinase and Ras/ERK pathways function as independent survival modules each of which inhibits a distinct apoptotic signaling pathway in sympathetic neurons. J Biol Chem. 2000;275:8817-8824.
75. Stadheim TA, Xiao H, Eastman A. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells. Cancer Res. 2001;61:1533-1540.
76. 2-terminal kinase-dependent p53-independent pathway. Cancer Res. 1999;59:3053-3058.
77. Wang TH, Popp DM, Wang HS, et al. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and independent pathways in ovarian cancer cells. J Biol Chem. 1999;274:8208-8216.
78. Phelan DR, Price G, Liu YF, Dorow DS. Activated JNK phosphorylates the C-terminal domain of MLK2 that is required for MLK2 induced apoptosis. J Biol Chem. 2001;276:10801-10810.
79. 2-terminal kinase/p38 mitogen-activated protein kinases. Cancer Res. 2001;61:8504-8512.